Maria Antonietta De Ioris, Coordinator: Neuroblastoma Working Group at AIEOP: Italian Association of Pediatric Hematology and Oncology, shared on LinkedIn:
“Proud to share our latest work, published in Translational Oncology.
A short dinutuximab beta schedule combined with TEMIRI showed encouraging activity, particularly at metastatic sites, with most responses achieved early.
Beyond response, our findings bring the complexity of GD2 expression into focus: a dynamic and heterogeneous target, varying across disease sites and over time.
As GD2-directed therapies become increasingly central in neuroblastoma, should longitudinal GD2 assessment become part of our treatment strategy?”
Title: Dinutuximab beta with TEMIRI chemotherapy in relapsed/refractory neuroblastoma: Real-world insights into the open question of GD2 expression
Authors: Maria Antonietta De Ioris, Francesca Del Bufalo, Concetta Quintarelli, Valentina Bertaina, Francesco Fabozzi, Maria Giuseppina Cefalo, Iside Alessi, Chiara Grimaldi, Maria Felicia Villani, Maria Luisa D’Andrea, Alessandra Stracuzzi, Claudio Altini, Carmen Malaspina, Matilde Sinibaldi, Stefano Di Cecca, Laura Iaffaldano, Clelia Geraci, Marco Becilli, Biagio De Angelis, Alessandro Crocoli, Giulia Cassanelli, Stefano Margaritora, Angela Mastronuzzi, Franco Locatelli
You can also read:
Giselle Sholler: Uniting Experts to Improve Outcomes for High-Risk Neuroblastoma
